Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Phase II Study of the mTOR Inhibitor Sirolimus in Neurofibromatosis Type 1 Related Plexiform Neurofibromas (Protocol 102)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified February 2014 by University of Alabama at Birmingham.
Recruitment status was  Active, not recruiting
Sponsor:
Collaborators:
Boston Children’s Hospital
Children's Hospital of Philadelphia
Children's Research Institute
Children's Hospital Medical Center, Cincinnati
National Cancer Institute (NCI)
University of Chicago
University of Utah
Washington University School of Medicine
Information provided by (Responsible Party):
University of Alabama at Birmingham
ClinicalTrials.gov Identifier:
NCT00634270
First received: February 20, 2008
Last updated: March 14, 2014
Last verified: February 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: August 2014
  Estimated Primary Completion Date: August 2014 (Final data collection date for primary outcome measure)